Shenzhen Hepalink Pharmaceutical Group Balance Sheet Health
Financial Health criteria checks 5/6
Shenzhen Hepalink Pharmaceutical Group has a total shareholder equity of CN¥12.2B and total debt of CN¥4.2B, which brings its debt-to-equity ratio to 34.8%. Its total assets and total liabilities are CN¥18.1B and CN¥5.9B respectively.
Key information
34.8%
Debt to equity ratio
CN¥4.25b
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥3.08b |
| Equity | CN¥12.21b |
| Total liabilities | CN¥5.91b |
| Total assets | CN¥18.12b |
Recent financial health updates
Here's Why Shenzhen Hepalink Pharmaceutical Group (SZSE:002399) Can Afford Some Debt
Oct 07
Here's Why Shenzhen Hepalink Pharmaceutical Group (SZSE:002399) Can Afford Some Debt
Jun 12Recent updates
Here's Why Shenzhen Hepalink Pharmaceutical Group (SZSE:002399) Can Afford Some Debt
Oct 07Some Shareholders Feeling Restless Over Shenzhen Hepalink Pharmaceutical Group Co., Ltd.'s (SZSE:002399) P/S Ratio
Aug 22Here's Why Shenzhen Hepalink Pharmaceutical Group (SZSE:002399) Can Afford Some Debt
Jun 12Shenzhen Hepalink Pharmaceutical Group Co., Ltd.'s (SZSE:002399) 26% Price Boost Is Out Of Tune With Revenues
May 06Financial Position Analysis
Short Term Liabilities: 002399's short term assets (CN¥10.4B) exceed its short term liabilities (CN¥4.3B).
Long Term Liabilities: 002399's short term assets (CN¥10.4B) exceed its long term liabilities (CN¥1.6B).
Debt to Equity History and Analysis
Debt Level: 002399's net debt to equity ratio (9.6%) is considered satisfactory.
Reducing Debt: 002399's debt to equity ratio has reduced from 91.2% to 34.8% over the past 5 years.
Debt Coverage: 002399's debt is well covered by operating cash flow (57.1%).
Interest Coverage: Insufficient data to determine if 002399's interest payments on its debt are well covered by EBIT.